Category Archives: Avandia

Featured Stories

National Law Firms Calls for More FDA Action on Actos Bladder Cancer Threat

A national law firm is not satisfied with the way the U.S. Food & Drug Administration (FDA) has handled warnings regarding Actos (pioglitazone) bladder cancer risks. In a statement published today, Parker Waichman LLP called on the FDA to compel Takeda Pharmaceuticals, the maker of the type 2 diabetes drug, ...

Read More

Cancer Groups Call for E-cigarettes Regulation/Research

Two-Leading-Cancer-Groups-Issue-Call-for-Regulation-of-E-cigarettes-and-Research-on-Health-Risks

The American Society of Clinical Oncology & the American Association for Cancer Research called for government regulation & research of e-cigarettes on health effects.

Read More

Crash on N.State Pkwy Kills Port Jefferson Station Man

Single-Car Crash on Northern State Parkway Kills Port Jefferson Station Man

A Port Jefferson Station man was killed on Wednesday due to a single-vehicle crash on the Northern State Parkway in Dix Hills. Police are investigating the accident, Newsday reports. According to Newsday, the 81-year-old man was driving a Nissan Altima west in the right lane, west of Exit 42. He ...

Read More

1,000+ Australians Join DePuy ASR Hip Implant Class Action Lawsuit

A class action lawsuit filed in Australia over DePuy Orthopaedics’ recalled metal-on-metal ASR Hip Implants has signed up more than 1,000 plaintiffs. The attorneys representing the Australian ASR Hip Implant lawsuit plaintiffs recently told The Courier-Mail that damages in the lawsuit are expected to be worth more than $200 million. One ...

Read More

Johnson & Johnson’s Ethicon Division to End Sales of Gynecare Prolift, Three Other Transvaginal Mesh Devices

Johnson & Johnson’s Ethicon Inc. division revealed yesterday that it will end sales of its Gynecare Prolift device and three other transvaginal mesh products. The plan to stop selling the four products was set forth in a letter filed by the company in the Ethicon transvaginal mesh multidistrict litigation ...

Read More

Federal Judge Certifies Medtronic Infuse Shareholder Class Action Lawsuit

A shareholder lawsuit alleging Medtronic Inc. illegally promoted the off-label use of its Infuse bone growth product has been granted class action status by U.S. District Judge Paul Magnuson of Minnesota. According to a report from Law360.com, the Medtronic Infuse off-label promotion lawsuit was filed by several institutional investors on ...

Read More

System for Tracking Prescription Drug Side Effects Flawed

Study Finds System for Tracking Prescription Drug Side Effects Flawed

System for keeping track of dangerous side effects of prescription drugs is flawed because drug makers are submitting incomplete information about problems to the FDA.

Read More

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

The U.S. Food & Drug Administration (FDA) is reviewing a new study that reported an increased risk of sudden, heart-related deaths among people using the antibiotic Zithromax (azithromycin), known popularly as Z-Pak. In a statement issued late yesterday, the FDA said patients being treated with Zithromax should not stop taking ...

Read More

Lawsuit Alleges Plavix Caused Oklahoma Man to Suffer Multiple Stomach Bleeds

Another lawsuit has been filed over adverse Plavix side effects. The lawsuit, filed by national law firm Parker Waichman LLP, alleges that the blood thinner, Plavix (clopidogrel), caused an Oklahoma man to suffer from multiple stomach bleeds.

Read More

Study Finds Plavix May Only Benefit Smokers

An emerging study finds that blood thinner Plavix may only benefit smokers. Plavix (clopidogrel) is prescribed for the prevention of blood clots and heart attacks, and has been linked to serious side effects, including the heart attacks and strokes it is supposed to prevent, gastrointestinal and cerebral bleeding, bleeding ulcers, ...

Read More

Mis-marketing of Drugs Cost Billions, Endangers Health

Mis-marketing of Drugs Cost Billions, Endangers Health

A new report from the Center for Economic and Policy Research (CEPR) describes the high costs associated with the mis-marketing of prescription drugs, both in dollars and in health consequences. Spending on prescription drugs has consistently been the fastest growing … Continue reading

Posted in Avandia, Defective Products, Health Concerns, Pharmaceuticals, Vioxx | Tagged , , , , |

Glaxo Agrees to $229 Million Avandia Settlement with Eight States

glaxo_avandia_settlement

In response to lawsuits brought by eight U.S. states, drug maker, GlaxoSmithKline, has agreed to pay hundreds of millions of dollars to settle actions over diabetes medication, Avandia (rosiglitazone). The drug maker announced it would pay $229 million and, in … Continue reading

Posted in Avandia, Pharmaceuticals |

Drug Maker, Roche, Ceases New Type 2 Diabetes Drug Testing Over Safety Risks

roche_diabetes_drugs

Drug maker, Roche, just announced it has stopped development of a diabetes drug that is in the same class as the Type 2 diabetes drugs Actos and Avandia. The move, according to The New York Times, could raise safety concerns … Continue reading

Posted in Actos, Avandia, Pharmaceuticals |

Diabetes Drug Fails to Cut Heart Risks, Clinical Trial Shows

onglyza_heart_health_ineffective

In a large clinical trial, Onglyza (saxagliptin), a Type 2 diabetes medication, failed to reduce the risk of heart attacks and related disease compared with a placebo. But the drug, co-marketed by Bristol-Myers Squibb and AstraZeneca, did not increase cardiovascular … Continue reading

Posted in Avandia, Health Concerns, Pharmaceuticals |

FDA Recommends Easing Avandia Restrictions

FDA_Avandia_Restrictions

A vote at the conclusion of a two-day meeting of United States health advisors ended with a recommendation to ease current market restrictions on Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. The U.S. Food and Drug Administration … Continue reading

Posted in Avandia, Legal News, Pharmaceuticals |

FDA Reconsidering its Stance on Avandia

FDA-Avandia-Restrictions

In an unprecedented move, the U.S. Food and Drug Administration is reopening the matter involving Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. Avandia belongs to a class of diabetes drugs called thiazolidinediones that lower blood sugar by … Continue reading

Posted in Avandia, Pharmaceuticals |

Financial ties between researchers, drug companies taint clinical data

Much of the so-called clinical data gathered to approve new prescription drugs or used to back marketing claims a company wishes to make about its products is likely soiled by financial ties between the person who wrote the research and … Continue reading

Posted in Avandia, Legal News, Pharmaceuticals | Tagged , , |

New study highlights risk of hip fractures associated with Actos

The findings of a new study should provide even more caution to those taking or considering Actos as a means of lowering their body’s glucose level. According to a study funded in part by the European Association for the Study … Continue reading

Posted in Actos, Avandia, Health Concerns, Legal News, Pharmaceuticals | Tagged , |

Glaxo to Resolve Avandia, Paxil, Wellbutrin Fraud Charges with Justice Department for Record-Breaking $3 Billion

The U.S. Justice Department has announced another record-breaking settlement with a pharmaceutical company accused of illegally marketing some of its drugs.  According to a statement issued by the Department late yesterday, GlaxoSmithKline will pay $3 billion to settle charges involving … Continue reading

Posted in Avandia, Pharmaceuticals, SSRI Antidepressants | Tagged |

Mediation Leads To Settlement Of 25,000 Avandia Lawsuits

Multidistrict litigation mediation has led to the settlement of about 25,000 Avandia lawsuits. Avandia was GlaskoSmithKline’s once-blockbuster type 2 diabetes drug. This November, U.S. District Judge Cynthia Rufe appointed a mediator to preside over settlement negotiation for the cases, setting … Continue reading

Posted in Avandia, Pharmaceuticals |

© 2005-2018 Parker Waichman LLP ®. All Rights Reserved.